Table 3 Antibiotic susceptibility patterns of GBS isolated from the newborns` body surfaces, Northwest Ethiopia

Penicillin

10units

Nasal nare (n=31)

29 (93.5)

0 (0.0)

2 (6.5)

Umbilicus (n=29)

26 (89.7)

0 (0.0)

3 (10.3)

Ear (n=21)

18 (85.7)

0 (0.0)

3 (14.3)

Ampicillin

10μg

Nasal nare (n=31)

29 (93.5)

0 (0.0)

2 (6.5)

Umbilicus (n=29)

28 (96.6)

0 (0.0)

1 (3.4)

Ear (n=21)

20 (95.2)

0 (0.0)

1 (4.8)

Erythromycin

15μg

Nasal nare (n=31)

24 (77.4)

2 (6.5)

5 (16.1)

Umbilicus (n=29)

21 (72.4)

1 (3.4)

7 (24.2)

Ear (n=21)

17 (80.9)

0 (0.0)

4 (19.1)

Clindamycin

2μg

Nasal nare (n=31)

24 (77.4)

1 (3.2)

6 (19.4)^a

Umbilicus (n=29)

22 (75.9)

2 (6.9)

5 (17.2)^a

Ear (n=21)

16 (76.2)

2 (9.5)

3 (14.3)^a

Azitromycin

15μg

Nasal nare (n=31)

27 (87.1)

1 (3.2)

3 (9.7)

Umbilicus (n=29)

22 (75.9)

4 (13.8)

3 (10.3)

Ear (n=21)

17 (80.9)

3 (14.3)

1 (4.8)

Vancomycin

30μg

Nasal nare (n=31)

26 (83.9)

0 (0.0)

5 (16.1)

Umbilicus (n=29 )

25 (86.2)

0 (0.0)

4 (13.8)

Ear (n=21)

18 (85.7)

0 (0.0)

3 (14.3)

Ceftriazone

30μg

Nasal nare (n=31)

23 (74.2)

0 (0.0)

8 (25.8)

Umbilicus (n=29)

22 (75.9)

0 (0.0)

7 (24.1)

Ear (n=21)

15 (71.4)

0 (0.0)

6 (28.6)

Ciprofloxacin

5μg

Nasal nare (n=31)

29 (93.5)

0 (0.0)

2 (6.5)

Umbilicus (n=29)

24 (82.8)

0 (0.0)

5 (17.2)

Ear (n=21)

19 (90.5)

0 (0.0)

2 (9.5)

Chloramphenicol

30μg

Nasal nare (n=31)

26 (83.9)

3 (9.6)

2 (6.5)

Umbilicus (n=29)

24 (82.8)

3 (10.3)

2 (6.9)

Ear (n=21)

19 (90.4)

1 (4.8)

1 (4.8)

Tetracycline

30μg

Nasal nare (n=31)

8 (25.8)

3 (9.7)

20 (64.5)

Umbilicus (n=29)

10 (34.5)

3 (10.3)

16 (55.2)

Ear (n=21)

9 (42.9)

0 (0.0)

12 (57.1)